Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
EARLY STAGE
 
My Lists

Neurogastrx

1608 W. Campbell Ave #210
Campbell, CA 95008
USA
Website Company Summary Management Team
Team

Management: Jim O'Mara (CEO/President) Cyril De Colle (Chief Scientific Officer)
Outside board: Aaron Royston (venBio Partners Partner) Klaus Veitinger (OrbiMed Venture Partner) David Allison (5AM Ventures Principal) Kevin Koch (Edgewise Therapeutics Former CEO)
Company

Business description: Neurogastrx, Inc. is a venture-stage biopharmaceutical company developing products for the treatment of gastrointestinal disorders. Neurogastrx is developing NG101 for the treatment of gastroparesis. We have generated preclinical data indicating that in addition to its potent antiemetic properties, NG101 is also expected to significantly increase gastric motility, conferring NG101 an ideal pharmacological profile for the treatment of gastroparesis.
Capital

Rounds: 1
Recent fundings: Jan 2018
Capital raised: 45.0M
Last Round: 45.0M
Ownership: Private  
VCs include: 5AM VenturesOrbiMedvenBio Partners

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2018
Sector: Medical
Year Founded: 2012
Rounds: 1
Recent fundings: Jan 2018
Capital raised: 45.0M
Last Round: 45.0M
Ownership: Private